By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

GENFIT Corp. 

245 First Street - 18th Floor
Suite 1806
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-444-8416 Fax: 617- 444-8405


SEARCH JOBS
Genfit is a biopharmaceutical company, listed on Alternext by Euronext™ Paris (ALGFT - FR0004163111) with headquarters in Lille, France and a US subsidiary in Cambridge, Massachusetts.

Through its world-renowned scientific expertise, particularly in the field of nuclear receptors, Genfit’s research efforts are focused on the discovery and development of new treatments mainly in the growing therapeutic areas of Cardiometabolic and Neurodegenerative disorders, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer’s. Genfit uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health problems and their unmet medical needs.

Genfit has an original business model built on both proprietary internal programs and a strong track record of partner-supported programs and collaborations. This strategy allows the company to efficiently manage the risks associated with the internal programs, and at the same time build value for its shareholders. Genfit, on its own or in collaboration with its major pharmaceutical partners, has thus created a rich and diversified pipeline of drug candidates in pre-clinical and clinical development, as well as a broad intellectual property portfolio.

Genfit’s strong portfolio of therapeutic products, tools, and clinical biomarkers, together with its scientific expertise, have made the Company into a European biotechnology leader.

GENFIT
Parc Eurasanté – Lille Metropole
885 Avenue Eugene Avinee
59120 Loos
France
Tel : +33 (0)3 2016 4000
Fax : +33 (0)3 2016 4001


Key Statistics


Email: Karen.Miller@Genfit.com
Ownership: Public

Web Site: GENFIT
Employees: 125 (Scientists: 100)
Symbol: ALGFT
 









Company News
GENFIT (ALGFT) – The NASH Education Programtm Announces The Launch Of The First International NASH Information Day On June 12, 2018: Save The Date! 7/14/2017 8:30:37 AM
GENFIT (ALGFT) Reaches A Critical Milestone Towards The Development Of A Non-Invasive In Vitro Diagnostic (IVD) Test For NASH 6/23/2017 10:38:12 AM
GENFIT (ALGFT) Reaches A Critical Milestone Towards The Development Of A Non-Invasive In Vitro Diagnostic (IVD) Test For NASH 6/23/2017 9:03:11 AM
GENFIT (ALGFT): Outcome Of The Ordinary And Extraordinary Shareholders’ Meeting Of June 16, 2017 6/19/2017 6:35:16 AM
GENFIT (ALGFT): Positive Outcome From The 1-Year Pre-Planned Safety Review By The DSMB, In RESOLVE-IT Phase III Clinical Trial With Elafibranor 6/1/2017 1:17:00 PM
GENFIT (ALGFT): Positive Outcome From The 1-Year Pre-Planned Safety Review By The DSMB, In RESOLVE-IT Phase III Clinical Trial With Elafibranor 6/1/2017 1:01:50 PM
GENFIT (ALGFT): Ordinary And Extraordinary Shareholders' Meeting Of June 16, 2017 - Availability Of Preparatory Documents 5/19/2017 10:05:39 AM
GENFIT (ALGFT) : Convening Notice To The Ordinary And Extraordinary Shareholders Meeting On June 16, 2017 5/15/2017 10:07:46 AM
GENFIT (ALGFT): First Patient Enrolled In A Phase II Trial Recruiting Adults With Primary Biliary Cholangitis (PBC), A Rare Liver Disease 5/5/2017 10:39:33 AM
GENFIT (ALGFT): First Patient Enrolled In A Phase II Trial Recruiting Adults With Primary Biliary Cholangitis (PBC), A Rare Liver Disease 5/5/2017 8:14:38 AM
12345678910...
//-->